BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,140 filers reported holding BAXTER INTL INC in Q4 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $212,370 | -15.1% | 4,751 | +5.8% | 0.27% | -23.5% |
| Q3 2022 | $250,000 | -24.7% | 4,492 | -20.6% | 0.35% | -19.2% |
| Q2 2022 | $332,000 | +12.9% | 5,659 | +51.2% | 0.44% | +15.9% |
| Q1 2022 | $294,000 | -2.6% | 3,742 | +8.8% | 0.38% | -5.8% |
| Q4 2021 | $302,000 | +28.0% | 3,439 | +17.3% | 0.40% | +10.5% |
| Q3 2021 | $236,000 | +11.8% | 2,931 | +11.8% | 0.36% | +8.4% |
| Q2 2021 | $211,000 | – | 2,621 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
| Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
| Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
| TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
| GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
| Third Point | 4,000,000 | $344,400,000 | 4.72% |
| Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
| Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
| Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
| Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |